Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125190131 | 12519013 | 1 | I | 20160425 | 20160505 | 20160701 | 20160701 | PER | GB-MHRA-TPP35581539C2704187YC1461600325254 | GB-LUPIN PHARMACEUTICALS INC.-E2B_00005429 | LUPIN | 76.00 | YR | F | Y | 0.00000 | 20160630 | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125190131 | 12519013 | 1 | PS | SIMVASTATIN. | SIMVASTATIN | 1 | Unknown | U | UNKNOWN | 78103 | |||||||||
| 125190131 | 12519013 | 2 | C | CETIRIZINE | CETIRIZINE HYDROCHLORIDE | 1 | Unknown | 0 | 1 | DF | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125190131 | 12519013 | 1 | Product used for unknown indication |
| 125190131 | 12519013 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125190131 | 12519013 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125190131 | 12519013 | Myalgia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125190131 | 12519013 | 1 | 20150422 | 0 | ||
| 125190131 | 12519013 | 2 | 20160421 | 0 |